<DOC>
	<DOCNO>NCT01180166</DOCNO>
	<brief_summary>The prognosis patient inoperable locally advance residual/relapsed gastric cancer rather poor . Concurrent capecitabine chemoradiotherapy safe recommend . Nimotuzumab , anti-EGFR ( epidermal growth factor receptor ) monoclonal antibody , show antitumor safety efficiency many phase I/II study . Efficiency combination treatment need analyze .</brief_summary>
	<brief_title>Combination Nimotuzumab , Capecitabine Radiotherapy Inoperable Recurrent Gastric Cancer</brief_title>
	<detailed_description>There standard treatment patient inoperable locally advance residual/relapsed gastric cancer . For former one , 5-fluorouracil ( 5-FU ) base concurrent chemoradiotherapy recommend treatment regimen . Concurrent capecitabine chemoradiotherapy show similar result . So far , study show drug target EGFRs play important role antitumor treatment . Nimotuzumab , anti-EGFR monoclonal antibody , show safety efficiency many phase I/II study . Because poor survival patient inoperable locally advance residual/relapsed gastric cancer , efficiency nimotuzumab plus concurrent capecitabine chemoradiotherapy need analyze .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1875 year old , male female Gastric cancer measurable lesion , diameter least 1 cm Karnofsky score : least 70 Estimated survival : least 6 month No prior target therapy radiotherapy No severe hypertension , cardiac disease , diabetes mellitus Normal blood routine chemical test Signed consent Other malignancy simultaneously except situ cervix nonmelanoma skin cancer Extensive distant metastasis Pregnancy lactation Allergic 5Fluorouracil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>concurrent chemoradiotherapy</keyword>
	<keyword>target therapy</keyword>
</DOC>